Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire de Nice
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Group 1
Available social insurance
Signed consent for the study enrollment
Age ≥ 18 years
Available social insurance
Signed consent for the study enrollment
Age ≥ 18 years
Available social insurance
Signed consent for the study enrollment
Age ≥ 18 years
Available social insurance
Signed consent for the study enrollment
Age ≥ 18 years
You may not be if
Patients in the group with metabolic fatty liver with hepatocellular carcinoma
Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women.
Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice.
No systemic HCC treatment in the previous 6 months
Group 2
Patients in the group with metabolic fatty liver without hepatocellular carcinoma
Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women.
Decision (less than 3 months) to perform a liver biopsy in routine practice. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients.
Group 3
Patients with an alcoholic liver disease with hepatocellular carcinoma
Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women.
Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice.
No systemic HCC treatment in the previous 6 months
Group 4
Patients with an alcoholic liver disease without hepatocellular carcinoma
Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women.
Decision (less than 3 months) to perform a liver biopsy in routine practice. No systemic HCC treatment in the previous 6 months. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients.
Clareo Health | Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease
